ZYBERNO
Stock Report
Updated Aug 21, 2026

Karyopharm Therapeutics Inc. (KPTI)

Healthcare • NASDAQ

$1.93

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
9.0/100
POOR BUSINESS
Karyopharm Therapeutics Inc. (KPTI) scores 9/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-56.2%)
Return on Capital (Capital Efficiency):CRITICAL (-109.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Karyopharm Therapeutics Inc. (KPTI) stock report — Zyberno Score 9/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, KPTI generated -$75.37M in Owner Earnings. Reinvestment rate: 0.5%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.93
Market Cap:$44.62M

Valuation Multiples (2)

P/S Ratio:0.30x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.22M

Price Action & Momentum (3)

Momentum Percentile:94 / 100
% of 52-Week High:17.6%
B. Profitability Assessment

Return Metrics (4)

ROA:-200.9%
Reinvestment Rate:0.5%
Fundamental Growth Rate (g):-0.5%

Margin Analysis (3)

Operating Margin Ttm:-56.2%
Net Margin Ttm:-153.3%
Ebitda Margin:-56.0%

TTM Performance (2)

Operating Margin Ttm:-56.2%
Net Margin Ttm:-153.3%

Yield Metrics (2)

Earnings Yield:-$723.62
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:55.5%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-0.7%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.79x
Quick Ratio:0.76x
Cash Ratio:0.41x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1.84x
Times Interest Earned:-1.84

Capital Structure (4)

Working Capital:-27,855,000.00
Cash And Cash Equivalents:54,980,000.00
Long Term Debt:$5.18M
Net Debt:-$43.40M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $146.62M
Linear Growth: -67.0%
📊 Click to view full KPTI Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$82.35M

Bottom Line Performance (3)

-$224.74M
Income Before Tax:-$224.77M
Ebitda Ttm:-82,120,000.00

Operating Expenses (5)

Operating Expenses:228,971,000.00
R And D Expense:120,965,000.00
Sga Expense:101,979,000.00
Income Tax Expense:$44.00K
Interest Expense:49,324,000.00

Expense Ratios (3)

R And D To Revenue Percentage:361.8%
Sga To Revenue Percentage:305.0%
Ebitda Margin:-56.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$111.32M
Current Assets:$106.38M
Ppe Net:94,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:441,485,000.00
Current Liabilities:134,233,000.00
Long Term Debt:$5.18M
Short Term Debt:$6.39M

Equity & Capital (3)

Equity:-$330.17M
Retained Earnings:-$1.85B
Common Stock:106,000,000.00

Working Capital Items (3)

Accounts Receivable:29,871,000.00
Inventory:3,994,000.00
Accounts Payable:78,804,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,929,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$59.11M-$75.37M

Investment Activities (2)

Investing Cash Flow:$3.20M
Capital Expenditures Ttm:0.00

Financing Activities (3)

Financing Cash Flow:$49.80M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:20,233,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:230,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-14.18
-$14.40
Earnings Per Share Ttm:-$9.72

Revenue & Cash Per Share (2)

Sales Per Share Ttm:6.34
Operating Cash Flow Per Share:-$3.26

Book Value & Capital (2)

Book Value Per Share:-$14.28
Cash Per Share:2.38

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.31x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:4.91x
Days Sales Outstanding Ttm:74.36

Inventory Management (2)

Inventory Turnover Ttm:36.71x
Days Inventory Outstanding Ttm:9.94

Payables & Cash Cycle (2)

Days Payable Outstanding:196.18
Cash Conversion Cycle:-111.87
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$75.37M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.5%
Fundamental Growth Rate (g):-0.5%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-0.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:KPTI
Company Name:Karyopharm Therapeutics Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:23.12M
Shares Outstanding Basic:28.94K
Shares Outstanding Diluted:28.94K

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-21 16:50:03 UTC
Data Timestamp:2026-08-18T22:37:25.259141
Scroll to Top